Gsa Capital Partners LLP Ligand Pharmaceuticals Inc Transaction History

Gsa Capital Partners LLP

$1.32 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$68.53 - $87.91 $97,244 - $124,744	1,419 Added 31.39%	5,939 $500,000
Q1 2024 May 03, 2024	BUY	$68.64 - $89.2 $310,252 - $403,184	4,520 New	4,520 $330,000
Q2 2023 Aug 14, 2023	BUY	$69.53 - $79.33 $263,171 - $300,264	3,785 New	3,785 $272,000
Q4 2022 Feb 13, 2023	BUY	$61.72 - $96.74 $1.29 Million - $2.02 Million	20,835 New	20,835 $1.39 Million
Q4 2020 Feb 03, 2021	SELL	$80.55 - $106.05 $521,964 - $687,204	-6,480 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$89.56 - $126.72 $580,348 - $821,145	6,480 New	6,480 $618,000
Q1 2020 May 12, 2020	SELL	$63.37 - $107.88 $335,987 - $571,979	-5,302 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$96.94 - $113.59 $184,379 - $216,048	1,902 Added 55.94%	5,302 $553,000
Q3 2019 Nov 12, 2019	SELL	$86.25 - $120.16 $607,803 - $846,767	-7,047 Reduced 67.45%	3,400 $338,000
Q2 2019 Aug 06, 2019	BUY	$107.38 - $129.34 $321,495 - $387,243	2,994 Added 40.17%	10,447 $1.19 Million
Q1 2019 May 15, 2019	SELL	$105.93 - $142.47 $177,962 - $239,349	-1,680 Reduced 18.39%	7,453 $937,000
Q4 2018 Feb 12, 2019	BUY	$128.36 - $272.13 $450,415 - $954,904	3,509 Added 62.39%	9,133 $1.24 Million
Q3 2018 Nov 13, 2018	SELL	$211.18 - $274.49 $388,148 - $504,512	-1,838 Reduced 24.63%	5,624 $1.54 Million
Q2 2018 Aug 09, 2018	SELL	$150.77 - $207.98 $1.15 Million - $1.59 Million	-7,639 Reduced 50.59%	7,462 $1.55 Million
Q1 2018 May 11, 2018	BUY	$138.63 - $182.62 $180,357 - $237,588	1,301 Added 9.43%	15,101 $2.49 Million
Q4 2017 Feb 14, 2018	BUY	$128.36 - $147.04 $1.77 Million - $2.03 Million	13,800	13,800 $1.89 Million

Others Institutions Holding LGND

# of Institutions

255

Shares Held

18.1M

Call Options Held

26.8K

Put Options Held

9.3K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.82B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account